All strengths: Limited Use, Reason for Use code 130, 412, 413 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 130, 412, 413 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Dysport Therapeutic · DIN 02460203 · 300U/Vial · Pd injection-vial
Limited Use, Reason for Use code 130, 412, 413 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 130 or 412 or 413 (criteria below)
Ontario Limited Use criteria, code 130, 412, 413
Coverage limit:
Dysport Therapeutic should be administered personally by a neurologist, pediatrician, or a physician with equivalent post-graduate training and experience with neuromuscular disorders.
Reason for Use code 130
To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 412
For the management of focal spasticity, due to stroke or spinal cord injury in adults.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 413
For the treatment of focal spasticity secondary to cerebral palsy in patients two years of age or older.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Dysport Therapeutic · DIN 02460203
Manufacturer: Ipsen Limited; listing date 2018-09-27
Health Canada: Marketed since 2022-04-06 · brand DYSPORT THERAPEUTIC · ATC M03AX01 BOTULINUM TOXIN · form Powder for solution · route Intramuscular · ingredients ABOBOTULINUMTOXINA 300 UNIT/VIAL · company Ipsen biopharmaceuticals canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordDysport Therapeutic: Formulary list price $385.56 per unit (the source does not state the unit; exact figure $385.5600). What the ministry pays, not the patient.
Ministry pays: $385.5600 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02460203)
Source record
DIN 02460203: Dysport Therapeutic
Raw flags: sec12=Y, sec3=Y
Item: 929200001; group id 1052; item number 2410; lccId 00308; manufacturer id IPS
Source form: Pd Inj-Vial Pk; strength: 300U/Vial
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $385.5600; ministry $385.5600
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02460203
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94749
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02460203
Shortage record checked October 6, 2026
Dysport Therapeutic · DIN 02456117 · 500U/Vial · Pd injection-vial
Limited Use, Reason for Use code 130, 412, 413 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 130 or 412 or 413 (criteria below)
Ontario Limited Use criteria, code 130, 412, 413
Coverage limit:
Dysport Therapeutic should be administered personally by a neurologist, pediatrician, or a physician with equivalent post-graduate training and experience with neuromuscular disorders.
Reason for Use code 130
To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 412
For the management of focal spasticity, due to stroke or spinal cord injury in adults.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 413
For the treatment of focal spasticity secondary to cerebral palsy in patients two years of age or older.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Dysport Therapeutic · DIN 02456117
Manufacturer: Ipsen Limited; listing date 2018-09-27
Health Canada: Marketed since 2022-04-06 · brand DYSPORT THERAPEUTIC · ATC M03AX01 BOTULINUM TOXIN · form Powder for solution · route Intramuscular · ingredients ABOBOTULINUMTOXINA 500 UNIT/VIAL · company Ipsen biopharmaceuticals canada inc · schedule Schedule d, Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordDysport Therapeutic: Formulary list price $642.60 per unit (the source does not state the unit; exact figure $642.6000). What the ministry pays, not the patient.
Ministry pays: $642.6000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456117)
Source record
DIN 02456117: Dysport Therapeutic
Raw flags: sec12=Y, sec3=Y
Item: 929200002; group id 1052; item number 2411; lccId 00308; manufacturer id IPS
Source form: Pd Inj-Vial Pk; strength: 500U/Vial
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $642.6000; ministry $642.6000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456117
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94296
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02456117
Shortage record checked October 6, 2026